Loktu laan, cancer cells dǝ kǝlanzǝlamen tumour dǝga sutuluyin kuru nasha gadero tartin nasha buye awu lymphatic system men, duluwu donyi metastasis lan notǝna ma.
Sa kansa dǝ tartǝna dǝn, kurun dio dǝ zau ro waljin.
Prostate cancer dǝ hormonal factors lan faltin, musamman maro hormone testosterone.
Testosterone dǝ ye cells donyi prostate cancer ye wurajin, kuru kurunwa prostate cancer ye nguwu saraana dǝ hormone adǝ ye fokta awu faidazǝ bannazǝ.
Kasarrataro, kanasar donyi suro be kuren wajin ma dǝ ye pathophysiologya nzǝ lan, kǝnzǝli donyi suro be kuren wajin ma dǝ ye kǝlanzǝ lan sǝta kǝlanzǝ ro yakkata ro, shi donyi geneticya, hormonya, a kǝndaram nzayeya so sha suwudin.
Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.
Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.
Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.
Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.
Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.
Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.
['Kәlanzәma ro cistәgә: liita']
['Websayit adә ilmu matәbe-a bayan matәbe bas nankaro cedo kuru shawari liyitabe au cidawa cidawu liyitabe diobe gәnyi.']
['Bayanwa yitagattәgәna so dә kwasa laa au kwasa laa asutu au kurun dio ro faidatәmba, kuru am doni shawaria liyitaye mazayin so dә dokta lasisatәna ro manatә saadin.']
['Martәne netәram kәrәnbe do korowa dә ro jawawu suwudin dә, taganasmaro kalkal gәnyi sa lamba isәna dәn. Misallo, nәm nguwu am doni kwasa laa taganasbe shiro asuzana ma.']
["Sambi so ro shawari kam litari nәm au kam gade nasha nәlewabe nozәna ma ye la'atar ro matәne. Shawari kam litaribe nozәna ma ro tәmmaro hangal gәnyi gәnane au sha matә lan loktu gozәnyi awo laa website adәn kәrәnәmma yen. Nyiye kurun nәlewabe batәrammin maa, talfon 911 lan buwoze au njim liwalabe karungu ma ro lenәme. Alaka nәlewa-a dondibe ba ma tuwandin web site adә men au shilan faidatәmen. BioMedLib-a cidawunzә-a, au kam do web site adә ro banazәyin-aye, affima bayanzәna au manazәna ma sadimba, bayanwa suro adәben tuwandin au shilan faidatәmen."]
['Suro nәm kәla nәm ngәla yen awo laa au kare laa kәla intanetndeyen au cidawandeyen mbejiye hakku nәm kakkadi ruotәbe nyiro kalzәna ma ye mbeji maa, nyi (au wakkilnәm) andero watiya zuwune awo au kare dә tutuluwu, au na dәro nazәgә dә tutuluwu.']
["Zande so dә ruwo lan zuzaiya, email men (adәretәm emailye dә nasha 'Lam'atarro manәmin)"]
['DMCA ye məradənzə bayan kəla nzətkawo kərmaabedəbe bayanwa anyi surodən mbejiro: (1) bayan kəla cida nzətkawobe dunonzə dunonzə kaltəgəbe dunonzə kaltəgəbe; (2) bayan kəla awoa zortəbe dunonzə kaltəgəbe dunonzə kuru bayan kəzəkə andeya səkə awoadəga fandəmin; (3) bayan kəlanəm lamba fantəbe, suro nzəranəm-a, lamba telehonbe-a kuru email-be-a; (4) bayan kəlanəmbe kəla nyiye tawatkənənde kəla awoa zortəbe dunonzə kaltəgəbe dunonzəye dunonzəye səkə au wakilinzəye, au shara laabe səkə; ']
['(5) bayan nyima, kalima jirebero, ruwotәgәna, bayan suro watiyade dә kalkalzәna kuru nyiye hakku kәlanzәbe hakkuwa ləbtәma soye warmatәgәbe dәga nonәmma;']
['kuru (6) mukko dunowa au lantarkibe hakkiwa ləbtamabe au kam laaye wakil zəben cida sədənabe. ']
['Bayanna samibe samma kәltәgә nyiye mowonzә zәktә lamar buruwunәmye gәrәmin.']
['Lǝtǝram']
['Martәne ande ro watiya emailye lan koro/shawari laa manane.']
What is pathophysiology of prostate cancer?
The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.
Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.
The prostate gland produces seminal fluid, which nourishes and transports sperm.
The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.
These include age, family history, race, and certain genetic mutations.
Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.
Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.
The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.
This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.
These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.
As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.
In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.
Once the cancer has spread, it can be more difficult to treat.
Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.
Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.
In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.
Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
